- PROFESSOR Population Health Science and Policy
Dr. Bagiella is Professor of Biostatistics in the Center for Biostatistics in the Department of Population Health Science & Policy at Mount Sinai School of Medicine. She also serves as Director, Biostatistics, Epidemiology and Research Design (BERD), at the MSSM CTSA, CONDUITS. She is Director of the “Reach for the First R01” and “Reach for the first K” course within CONDUITS. She has extensive experience in clinical trial methodology and the design and analysis of longitudinal studies. She also has a methodological interest in outcome assessment and the issues related to evaluating outcomes in different populations. She has served as a DSMB member for clinical trials in Neurology, Cardiology and HIV.
Bagiella E, Novack TA, Ansel B, Diaz-Arrastia R, Dikmen S, Hart T, Temkin N. Measuring Outcome in TBI Treatment Trials: Recommendations from the TBI Clinical Trials Network. Journal of Head Trauma and Rehabilitation 2010; 25(5): 375-82.
Bagiella E. Clinical trials in rehabilitation; Single or Multiple Outcomes? . Arch Phys Med Rehabil 2009; 90: S17-21.
Sloan RP, Shapiro PA, DeMeersman RE, Bagiella E, Brondolo EN, McKinley PS, Slavov L, Fang Y, Myers MM. The effect of aerobic training and cardiac autonomic regulation in young adults. American Journal of Public Health 2009; 99(5): 921-8.
Kelvin EA, Carpio A, Hesdorffer DC, Bagiella E, Leslie D, Leon P, Andrews H, Hauser WA, Ecuadorian Neurocysticercosis Group . Investigation of familial aggregation of seizures in neurocysticercosis patients. Epilepsy Research 2009; 84(1): 67-71.
Benn EK, Hauser WA, Shih T, Leary L, Bagiella E, Dayan P, Green R, Andrews H, Thurman DJ, Hesdorffer DC. Underlying cause of death in incident unprovoked seizures in the urban community of Northern Manhattan, New York City. Epilepsia 2009; 50(10): 2296-300.
Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews A, Hauser WA, and The Ecuadorian Neurocysticercosis Group The Ecuadorian Neurocysticercosis Group . The effects of albendazole treatment on neurocysticercosis: a randomized controlled trial. Journal of Neurology, Neurosurgery & Psychiatry. The Ecuadorian Neurocysticercosis Group 2008; 79(9): 1050-5.
Benn EK, Hauser WA, Shih T, Leary L, Bagiella E, Green R, Andrews H, Thurman DJ, Hesdorffer DC. Estimating the incidence of first unprovoked seizure and newly diagnosed epilepsy in the low-income urban community of Northern Manhattan, New York City. Epilepsia 2008; 49(8): 1431-9.
Kelvin EA, Hesdorffer DC, Bagiella E, Andrews H, Pedley TA, Shih TT, Leary L, Thurman DJ, Hauser WA. Prevalence of self-reported epilepsy in a multiracial and multiethnic community in New York City. Epilepsy Res 2007; 77(2-3): 141-50.
Yegen HA, Lederer DJ, Barr RG, Wilt JS, Fang Y, Bagiella E, D'Ovidio F, Okun JM, Sonett JR, Arcasoy SM, Kawut SM. Risk factors for venous thromboembolism after lung transplantation. Chest 2007; 132(2): 547-53.
Lederer DJ, Arcasoy SM, Barr RG, Wilt JS, Bagiella E, D'Ovidio F, Sonett JR, Kawut SM. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant 2006; 6: 2436-2442.
Bagiella E. Estimating and comparing the distribution of onset of disease from prevalence case-control data. Biometrics. 2006; 62(1): 54-60.2.
Norton RM, Sloan RP, Bagiella E. A new approach to the statistical analysis of cardiovascular data. Journal of Applied Physiology 2005; 98: 2298-2303.
Bagiella E, Heitjan DF. Predicting interim analysis times in Randomized Clinical Trials. Statistics in Medicine 2001; 20(14): 2055-63.
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001; 7(5): 1192-7.
Bagiella E, Rabinowitz D. Estimating the distribution of age at onset from case-control family data. Statistica Sinica 2000; 10(4): 1179-1198.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Bagiella during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.
- PRA International
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 2nd Floor Room L2-36
1425 Madison Avenue
New York, NY 10029